Mettler-Toledo shares show bullish potential with a 13.7% upside target after beating Q2 earnings expectations and raising full-year guidance, even as the stock trails the broader Nasdaq Composite's 52-week performance.
Mettler-Toledo beat EPS estimates, raised full-year guidance, and has a Moderate Buy consensus with 13.7% upside, despite recent underperformance.
Nasdaq Composite index rose 19.5% over 52 weeks, outperforming MTD.
Quest Diagnostics shares have outperformed MTD over the past 52 weeks, but the article does not provide further details.
Mettler-Toledo International (MTD) reported a strong Q2 2026, with adjusted EPS of $11.46 beating analyst estimates and revenue hitting $1 billion. The company raised its full-year EPS guidance to $47.33, signaling improved profitability despite the stock trading below its 50-day and 200-day moving averages.
While MTD has outperformed the Nasdaq Composite over the last three months with 14.4% growth, it has lagged significantly over the past 52 weeks, rising only 2.8% compared to the index's 19.5% gain.